.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Express Scripts
Cerilliant
Mallinckrodt
Merck
Novartis
US Army
Cipla
Citi

Generated: December 14, 2017

DrugPatentWatch Database Preview

Endo Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for ENDO PHARMS, and what generic alternatives to ENDO PHARMS drugs are available?

ENDO PHARMS has twenty-one approved drugs.

There are twenty-six US patents protecting ENDO PHARMS drugs on ENDO PHARMS drugs in the past three years.

There are four hundred and seventy patent family members on ENDO PHARMS drugs in forty-five countries and seven supplementary protection certificates in four countries.

Summary for Endo Pharms

International Patents:470
US Patents:26
Tradenames:17
Ingredients:15
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Endo PharmsNUMORPHANoxymorphone hydrochlorideSUPPOSITORY;RECTAL011738-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Endo PharmsHYCODANhomatropine methylbromide; hydrocodone bitartrateTABLET;ORAL005213-001Jul 26, 1988DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Endo PharmsMOBANmolindone hydrochlorideTABLET;ORAL017111-004Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-006Dec 9, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-001Dec 9, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-001Dec 9, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Endo PharmsMOBANmolindone hydrochlorideTABLET;ORAL017111-005Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-002Jun 22, 2006DISCNNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-006Dec 9, 2011DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL201655-004Dec 9, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Endo Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-007Feb 29, 2008► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-003Jun 22, 2006► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-005Feb 29, 2008► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-004Jun 22, 2006► Subscribe► Subscribe
Endo PharmsMOBANmolindone hydrochlorideTABLET;ORAL017111-007Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Endo PharmsMOBANmolindone hydrochlorideTABLET;ORAL017111-008Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-003Jun 22, 2006► Subscribe► Subscribe
Endo PharmsMOBANmolindone hydrochlorideTABLET;ORAL017111-006Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Endo PharmsMOBANmolindone hydrochlorideTABLET;ORAL017111-005Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Endo PharmsOPANA ERoxymorphone hydrochlorideTABLET, EXTENDED RELEASE;ORAL021610-006Feb 29, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ENDO PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
cyanocobalaminNasal Spray500 mcg/sprayNASCOBAL4/28/2017
testosterone undecanoateInjection250 mg/mLAVEED6/11/2014
testosteroneGel10 mg/actuationFORTESTA8/14/2012
frovatriptan succinateTablets2.5 mgFROVA3/9/2011
oxymorphone hydrochlorideExtended-release Tablets30 mgOPANA ER6/12/2008
oxymorphone hydrochlorideExtended-release Tablets7.5 mg and 15 mgOPANA ER5/29/2008
oxymorphone hydrochlorideExtended-release Tablets5 mg, 10 mg, 20 mg and 40 mgOPANA ER11/23/2007

Non-Orange Book Patents for Endo Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,998,507Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors► Subscribe
7,927,627Nanoparticulate fibrate formulations► Subscribe
6,969,529 Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers► Subscribe
8,236,352Glipizide compositions► Subscribe
7,695,739In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
7,320,802Methods of treatment using nanoparticulate fenofibrate compositions► Subscribe
7,157,097Penetration enhancing and irritation reducing systems► Subscribe
8,309,136In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions► Subscribe
8,652,464Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer► Subscribe
7,198,795In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Endo Pharms Drugs

Country Document Number Estimated Expiration
Germany60223254► Subscribe
Japan2010013462► Subscribe
China101652371► Subscribe
Japan2008546796► Subscribe
Australia2004218893► Subscribe
Japan4440635► Subscribe
Germany502004003234► Subscribe
Germany10336400► Subscribe
Denmark1510213► Subscribe
Germany102004032051► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Endo Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0003France► SubscribePRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920
02/028Ireland► SubscribePRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
C0019France► SubscribePRODUCT NAME: FROVATRIPTAN SUCCINATE MONOHYDRATE; NAT. REGISTRATION NO/DATE: NL 24548 20001212; FIRST REGISTRATION: FR - NL 24548 20001212
C/GB03/014United Kingdom► SubscribePRODUCT NAME: 3 METHYLAMINO-6-CARBOXAMIDO-1, 2, 3, 4-TETRAHYDROCARBAZOLE ("FROVATRIPTAN") INCLUDING A SALT, SOLVATE OR HYDRATE THEREOF; REGISTERED: FR NL 24548 20001212; UK PL 16239/0017 20021007; UK PL 16239/0018 20021007
00103Netherlands► SubscribePRODUCT NAME: FROVATRIPTAN EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 27211RVG 27212 2002190419; FIRST REGISTRATION: NL 24548 20001212
00071Netherlands► SubscribePRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
C/GB02/027United Kingdom► SubscribePRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Accenture
Fish and Richardson
AstraZeneca
Deloitte
Fuji
Federal Trade Commission
Healthtrust
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot